Shilpa Medicare’s Telangana facility gets Health Canada GMP approval

01 Dec 2022 Evaluate

Shilpa Medicare’s finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Telangana has received Health Canada GMP approval for the inspection conducted from September 12, 2022 to September 16, 2022. The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy. This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada.  This approval reaffirms the company’s focused efforts to maintain the GMP status up to the standards of global regulatory authorities. 

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

331.30 -2.65 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×